Halozyme Therapeutics, Inc. (HALO)
65.16
-1.19
(-1.79%)
USD |
NASDAQ |
May 07, 15:44
Halozyme Therapeutics SG&A Expense (TTM) : 207.09M for Dec. 31, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Vertex Pharmaceuticals, Inc. | 1.357B |
| Eli Lilly & Co. | 11.56B |
| Johnson & Johnson | 24.60B |
| Baxter International, Inc. | 2.915B |
| Glaukos Corp. | 354.02M |